Systems approaches to drug discovery and development in oncology
Edited by org.aimpl.user:jpw@mit.edu
This document summarizes the eleven questions reviewed as a group in the Friday session, indicates sub-points for each question, and leverages available data and literature in better detailing each question. It contents are based on the discussion Friday, as well as the many points raised during Thursday’s brainstorming session.
The questions are divided into four parts: (1) questions voted as the top four most important problem areas for the field; (2) biology-centric problem areas; (3) modeling-centric problem areas; and (4) mechanisms of industrial-academic collaborations. The collaborations topic was set in its own category because it involves both biology and modeling questions, but also because it largely emphasizes cultural aspects in bringing industry and academia together rather than research questions per se.
The questions are divided into four parts: (1) questions voted as the top four most important problem areas for the field; (2) biology-centric problem areas; (3) modeling-centric problem areas; and (4) mechanisms of industrial-academic collaborations. The collaborations topic was set in its own category because it involves both biology and modeling questions, but also because it largely emphasizes cultural aspects in bringing industry and academia together rather than research questions per se.
Sections
Cite this as: AimPL: Systems approaches to drug discovery and development in oncology, available at http://aimpl.org/systemsoncology.